Prolia (denosumab; Amgen/Daiichi Sankyo) Drug Overview 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Drug Overview: Prolia" report has been added to ResearchAndMarkets.com's offering.

Prolia (denosumab; Amgen/Daiichi Sankyo) is a fully human monoclonal antibody developed by Amgen for the treatment of osteoporosis. Prolia acts by binding to the receptor activator for nuclear factor kappa B ligand (RANKL), preventing activation of its receptor, RANK. The inhibition of this interaction acts to decrease bone resorption, reducing bone turnover and increasing bone mass and strength by inhibition of osteoclastogenesis and osteoclast activity.

Key Topics Covered:

OVERVIEW

Drug Overview

Product Profiles

Prolia: Osteoporosis

List of Figures

Figure 1: Prolia for osteoporosis - SWOT analysis

Figure 2: Drug assessment summary of Prolia for osteoporosis

Figure 3: Drug assessment summary of Prolia for osteoporosis

List of Tables

Table 1: Prolia drug profile

Table 2: Prolia pivotal trial data in osteoporosis

Table 3: Prolia late-phase trial data in osteoporosis

For more information about this report visit https://www.researchandmarkets.com/research/5s3btd/prolia?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs